0001372514-24-000096.txt : 20240703 0001372514-24-000096.hdr.sgml : 20240703 20240703151641 ACCESSION NUMBER: 0001372514-24-000096 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240701 FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tosca Melissa CENTRAL INDEX KEY: 0001947184 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 241099811 MAIL ADDRESS: STREET 1: C/O KIORA PHARMACEUTICALS, INC. STREET 2: 1371 EAST 2100 SOUTH, SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: 781-788-8869 MAIL ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 4 1 wk-form4_1720034195.xml FORM 4 X0508 4 2024-07-01 0 0001372514 KIORA PHARMACEUTICALS INC KPRX 0001947184 Tosca Melissa C/O KIORA PHARMACEUTICALS, INC. 332 ENCINITAS BLVD., SUITE 102 ENCINITAS CA 92024 0 1 0 0 CFO 0 Common Stock 2024-07-01 4 A 0 7620 0 A 11599 D Stock Option (right to buy) 4.35 2024-07-01 4 A 0 15239 0 A 2025-07-01 2034-07-01 Common Stock 15239 15239 D Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of July 1, 2025, July 1, 2026 and July 1, 2027, subject to the reporting person's continuous service through each such vesting date. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on July 1, 2025, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. /s/ Melissa Tosca, Attorney-in-Fact 2024-07-03